UK experience of proton pump inhibitor related interstitial nephritis

Introduction We have previously highlighted the association between proton pump inhibitors (PPIs) and allergic-type acute interstitial nephritis (AIN) as a cause of kidney injury.1 The current study was designed to assess the UK experience of this condition by Consultant Nephrologists both within th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2011-04, Vol.60 (Suppl 1), p.A176-A176
Hauptverfasser: Gounaris-Shannon, N, Benning, J, Delaney, M, Muller, A F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction We have previously highlighted the association between proton pump inhibitors (PPIs) and allergic-type acute interstitial nephritis (AIN) as a cause of kidney injury.1 The current study was designed to assess the UK experience of this condition by Consultant Nephrologists both within the past 12 months and lifetime experience and compare this to cases reported to the Medicines and Healthcare products Regulatory Agency, MHRA. Methods UK nephrologists, identified from British Renal Society workforce planning database and membership lists from the UK Renal Association, were asked to respond to a specific questionnaire asking of their experience of PPI induced AIN in the 12 month period January – December 2009 and lifetime experience. Since responses were received from more than one consultant in each renal unit, the highest number of cases reported by one individual from each unit was recorded to minimise potential for duplication. The MHRA Drug Analysis Prints were analysed for each of the PPI drugs available2 to identify how many cases had been reported over the same timescale. Results Results were obtained from a total of 56 UK renal units and are summarised in table 1. Table 1 PWE-112 Reported cases from 56 UK renal units MHRA reported cases UK nephrologists lifetime experience Jan-Dec 2009 Total since PPIs introduced 321 91 75 The UK experience of PPI associated AIN in the 12 month period of 2009 was larger than the total number of cases reported to the MRHA since PPI's were introduced in the 1980s. Conclusion Although Gastroenterologists are largely unfamiliar with this complication of PPIs, the experience of UK Nephrologists would suggest that it is a more common side effect than had previously been appreciated and that unsurprisingly the number of cases reported to the MRHA represents a significant under reporting of the problem. Gastroenterologists reviewing patients treated with PPIs with troublesome but perhaps non-specific symptoms or in whom there is evidence of abnormal or declining kidney function should consider PPIs as a possible cause.
ISSN:0017-5749
1468-3288
DOI:10.1136/gut.2011.239301.375